Peptide-Based Metabolic Disorders Therapeutics Market is Estimatd to Reach US$ 77.9 Billion by 2033

The global Peptide-Based Metabolic Disorders Therapeutics Market, valued at US$ 25 billion in 2023, is projected to grow at a stellar compound annual growth rate (CAGR) of 12%, reaching US$ 77.9 billion by 2033. This comprehensive report from Fact.MR provides critical insights into market trends, technological advancements, and growth opportunities, offering actionable guidance for stakeholders in pharmaceuticals, biotechnology, and healthcare sectors.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=187

What Are the Key Market Insights?

The peptide-based metabolic disorders therapeutics market is experiencing robust growth, driven by the rising prevalence of metabolic disorders such as diabetes, obesity, and metabolic syndrome, fueled by sedentary lifestyles, poor dietary habits, and an aging global population. Peptide therapeutics, including GLP-1 receptor agonists like liraglutide and exenatide, offer high specificity, low toxicity, and the ability to target complex biological pathways, making them ideal for managing conditions like type 2 diabetes and obesity. Advancements in peptide synthesis, such as solid-phase peptide synthesis (SPPS) and hybrid technologies, have improved drug stability and bioavailability, enhancing therapeutic outcomes.

Supportive government initiatives and increased R&D investments by pharmaceutical companies are accelerating the development of novel peptide therapies. Challenges include high production costs, complex manufacturing processes, and competition from alternative treatments like small-molecule drugs. Opportunities are emerging in personalized medicine and the development of oral peptide formulations, particularly in high-growth regions like Asia-Pacific, where rising healthcare investments are driving demand.

What Are the Key Statistics and Forecasts?

The report provides precise data to inform strategic decision-making. In 2023, the global peptide-based metabolic disorders therapeutics market is valued at US$ 25 billion, with a projected CAGR of 12% through 2033, reaching US$ 77.9 billion. The U.S. is the most attractive market, expected to maintain dominance due to its advanced healthcare infrastructure and high prevalence of metabolic disorders.

North America holds a significant share, while Asia-Pacific is poised for rapid growth due to increasing healthcare expenditure and biotechnology advancements. The metabolic disorders segment, particularly for diabetes and obesity, dominates with a 27.9% market share in 2024, driven by the widespread use of GLP-1 receptor agonists. The market's historical growth from 2018 to 2022 was at a CAGR of approximately 5.8%, indicating an accelerating trajectory fueled by technological advancements and rising demand.

How Can Industries Benefit from the Report?

Fact.MR's report offers tailored insights for various industries. Pharmaceutical and biotechnology companies can leverage the findings to develop innovative peptide therapies, such as GLP-1 receptor agonists, to address unmet needs in diabetes and obesity management, enhancing patient outcomes. Academic and research institutes benefit from insights into advanced peptide synthesis and delivery technologies, fostering innovation in personalized medicine. Contract research organizations (CROs) can expand service offerings by supporting clinical trials for novel peptide drugs.

The report also aids manufacturers by highlighting opportunities to develop cost-effective, high-efficacy peptides, including biosimilars, to meet growing demand in emerging markets. By analyzing market dynamics, regulatory frameworks, and consumer trends, the report empowers stakeholders to optimize R&D investments, streamline production, and strengthen their competitive positioning.

Browse Full Report: https://www.factmr.com/report/187/peptide-based-metabolic-disorders-therapeutics-market

Who Published the Report, and Where Can It Be Accessed?

Fact.MR, a trusted market research firm serving 80% of Fortune 1,000 companies, authored this report. With over 600 domain experts and a database exceeding 100 million data points, Fact.MR employs a rigorous methodology combining qualitative and quantitative research, including stakeholder interviews, market surveys, and advanced analytics, to ensure accuracy and reliability.

Who Are the Key Players?

The peptide-based metabolic disorders therapeutics market is driven by leading companies focused on innovation and quality. Prominent players include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca Plc, Sanofi, Merck & Co., Inc., and Amgen Inc. These companies are investing heavily in R&D to develop novel peptide drugs, such as biosimilars and next-generation GLP-1 receptor agonists, and forming strategic partnerships to enhance their market presence. For example, in January 2024, Glenmark Pharmaceuticals Ltd. launched Lirafit, a liraglutide biosimilar, to address diabetes and obesity at a lower cost.

What Are the Recent Developments in the Market?

Recent advancements in the peptide-based metabolic disorders therapeutics market highlight a focus on innovation and accessibility. In February 2025, Biocon launched a liraglutide biosimilar in the UK, marketed as Liraglutide Biocon for diabetes and Biolide for weight management, reducing therapy costs by approximately 70%. In December 2023, Roche acquired Carmot Therapeutics for US$ 2.7 billion, gaining access to CT-388, a dual GLP-1/GIP receptor agonist in Phase 2 trials for obesity and diabetes.

The integration of AI and computational modeling is accelerating peptide drug discovery, improving efficacy and reducing development timelines. Additionally, advancements in oral peptide formulations and delivery systems, such as nanoparticle-based technologies, are enhancing patient compliance by overcoming challenges associated with parenteral administration. These developments, coupled with growing clinical trials for metabolic disorders, are shaping the market's future and expanding its therapeutic potential.

Check out More Related Studies Published by Fact.MR:

Peptide Based Hematological Disorders Therapeutics Market: https://www.factmr.com/report/189/peptide-based-hematological-disorders-therapeutics-market

Peptide Based Gastrointestinal Disorders Therapeutics Market: https://www.factmr.com/report/190/peptide-based-gastrointestinal-disorders-therapeutics-market

Peptide-based Cardiovascular Therapeutics Market: https://www.factmr.com/report/191/peptide-based-cardiovascular-therapeutics-market

Peptide-based Infection Therapeutics Market: https://www.factmr.com/report/188/peptide-based-infection-therapeutics-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.